Review Highlights Role of Arginine Methylation in Immunoregulation and Inflammaging

A scientific review published in Cell Chemical Biology outlines how protein arginine methyltransferases regulate immune cells and chromatin, identifying arginine methylation as a potential therapeutic target for age-associated inflammaging.

On October 5, 2026, researchers from the University of Tsukuba and partner Japanese institutions published a review in Cell Chemical Biology examining the role of protein arginine methylation in immune cell regulation.

The review details how protein arginine methyltransferases (PRMTs) modify histone and non-histone substrates, acting as crucial links between epigenetic control, RNA metabolism, and intracellular signal transduction.

The authors highlight that while normal PRMT activity shapes immune homeostasis and activation, dysregulated arginine methylation is increasingly linked to chronic inflammation, tumor immune evasion, and age-associated immune remodeling (inflammaging).

Inflammaging—the chronic, low-grade inflammation that characterizes aging—is a major driver of age-related systemic decline. Understanding the epigenetic and signaling mechanisms, such as PRMT-mediated arginine methylation, provides a precise biochemical framework for developing targeted interventions.

By coordinating chromatin regulation and RNA metabolism, PRMTs represent multi-layered therapeutic targets that could potentially reprogram senescent or dysfunctional immune cells back toward homeostasis.

The identification of PRMTs as key regulators of immunosenescence and inflammaging could stimulate drug discovery efforts focused on selective PRMT inhibitors or modulators.

While PRMT inhibitors are primarily investigated in oncology, this review supports the expanding therapeutic scope of epigenetic modifiers into the longevity and healthy aging sectors, particularly for addressing chronic inflammatory states.

Preclinical studies evaluating selective PRMT modulators in models of age-related chronic inflammation and immune decline to validate their therapeutic utility.